Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $1,750 | 8 | 65.7% |
| Food and Beverage | $913.31 | 18 | 34.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,728 | 14 | $0 (2024) |
| Merck Sharp & Dohme LLC | $658.88 | 6 | $0 (2024) |
| Novo Nordisk Inc | $105.99 | 1 | $0 (2017) |
| Medtronic Vascular, Inc. | $86.95 | 1 | $0 (2017) |
| GlaxoSmithKline, LLC. | $39.39 | 2 | $0 (2017) |
| Janssen Pharmaceuticals, Inc | $33.33 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $11.02 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,387 | 20 | E.R. Squibb & Sons, L.L.C. ($1,728) |
| 2017 | $276.68 | 6 | Novo Nordisk Inc ($105.99) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $35.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/13/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Food and Beverage | In-kind items and services | $30.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | In-kind items and services | $234.01 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 11/12/2024 | Merck Sharp & Dohme LLC | LAGEVRIO (Biological) | Travel and Lodging | Cash or cash equivalent | $95.86 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $538.20 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $225.94 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $225.94 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $155.86 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $140.71 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $75.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $70.00 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $40.66 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/10/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $27.73 | General |
| 10/16/2017 | Medtronic Vascular, Inc. | Claria MRI (Device) | Food and Beverage | In-kind items and services | $86.95 | General |
| Category: Cardiac Resynchronization Therapy - CRT | ||||||
| 10/14/2017 | Janssen Pharmaceuticals, Inc | INVOKANA (Drug) | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/21/2017 | GlaxoSmithKline, LLC. | ADVAIR (Drug), FLOVENT | Food and Beverage | In-kind items and services | $15.14 | General |
| Category: RESPIRATORY | ||||||
| 09/05/2017 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.02 | General |
| Category: CARDIOVASCULAR | ||||||
| 05/18/2017 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $105.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 226 | 473 | $76,676 | $30,402 |
| 2022 | 7 | 190 | 395 | $57,652 | $26,087 |
| 2021 | 10 | 389 | 586 | $47,208 | $30,458 |
| 2020 | 7 | 169 | 362 | $49,740 | $22,761 |
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | Office | 2021 | 13 | 13 | $780.00 | $381.81 | 49.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 33 | 125 | $24,820 | $10,790 | 43.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 20 | 47 | $5,210 | $3,054 | 58.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 24 | 24 | $3,600 | $3,007 | 83.5% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Office | 2020 | 30 | 88 | $6,160 | $2,484 | 40.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 29 | $7,250 | $2,470 | 34.1% |
| G0442 | Annual alcohol misuse screening, 15 minutes | Office | 2020 | 25 | 25 | $1,500 | $488.05 | 32.5% |
| G0444 | Annual depression screening, 15 minutes | Office | 2020 | 24 | 24 | $1,200 | $468.45 | 39.0% |
About Dr. Ciro Ramirez, M.D
Dr. Ciro Ramirez, M.D is a Internal Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/16/2008. The National Provider Identifier (NPI) number assigned to this provider is 1558547844.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ciro Ramirez, M.D has received a total of $2,664 in payments from pharmaceutical and medical device companies, with $2,387 received in 2024. These payments were reported across 26 transactions from 7 companies. The most common payment nature is "Travel and Lodging" ($1,750).
As a Medicare-enrolled provider, Ramirez has provided services to 974 Medicare beneficiaries, totaling 1,816 services with total Medicare billing of $109,708. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Miami, FL
- Active Since 01/16/2008
- Last Updated 02/13/2014
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1558547844
Products in Payments
- LAGEVRIO (Biological) $658.88
- Claria MRI (Device) $86.95
- ADVAIR (Drug) $39.39
- INVOKANA (Drug) $33.33
- ENTRESTO (Drug) $11.02
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Miami
Jay Skyler, Md, MD
Internal Medicine — Payments: $2.9M
Dr. Lukasz Kwapisz
Internal Medicine — Payments: $800,664
Mark Kutner, Md, MD
Internal Medicine — Payments: $610,516
Dr. Ian Del Conde Pozzi, M.d, M.D
Internal Medicine — Payments: $499,756
Mr. Angel Carrasco, M.d, M.D
Internal Medicine — Payments: $493,362
Dr. Edward Mezerhane, Md, MD
Internal Medicine — Payments: $470,504